Skip to main content
SpringerLink
Log in

Older pharmacological therapies for stress urinary incontinence are often unreliable, but duloxetine is a promising new option

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

References

  1. Zinner RN, Koke SC, Viktrup L. Pharmacotherapy for stress urinary incontinence: present and future options. Drugs 2004; 64(14): 1503–16

    Article  PubMed  Google Scholar 

  2. Kinchen KS, Bump RC, Gohier J. Prevalence and frequency of stress urinary incontinence among community-dwelling women [abstract]. Eur Urol Suppl 2002; 1(1): 85

    Article  Google Scholar 

  3. Fultz NH, Burgio K, Diokno AC, et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003; 189(5): 1275–82

    Article  PubMed  Google Scholar 

  4. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2003 (2): CD001405

  5. Al-Badr A, Ross S, Soroka D, et al. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? J Obstet Gynaecol Can 2003; 25(7): 567–74

    PubMed  Google Scholar 

  6. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97(1): 116–20

    Article  PubMed  CAS  Google Scholar 

  7. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343(25): 1826–32

    Article  PubMed  CAS  Google Scholar 

  8. Weil EH, Eerdmans PH, Dijkman GA, et al. Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9(3): 145–50

    Article  PubMed  CAS  Google Scholar 

  9. Radley SC, Chappie CR, Bryan NP, et al. Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study. Neurourol Urodyn 2001; 20(1): 43–52

    Article  PubMed  CAS  Google Scholar 

  10. Yasuda K, Kawabe K, Takimoto K. A double-blind clinical trial of a β2-adrenergic agonist in stress incontinence [abstract]. Int Urogynecol J 1993; 4: 146

    Article  Google Scholar 

  11. Ishiko O, Ushiroyama T, Saji F, et al. Beta (2)-adrenergic agonists and pelvic floor exercises for female stress incontinence. Int J Gynaecol Obstet 2000; 71(1): 39–44

    Article  PubMed  CAS  Google Scholar 

  12. Gilja I, Radej M, Kovacic M, et al. Conservative treatment of female stress incontinence with imipramine. J Urol 1984; 132(5): 909–11

    PubMed  CAS  Google Scholar 

  13. Lin HH, Sheu BC, Lo MC, et al. Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol 1999; 106(10): 1089–92

    Article  PubMed  CAS  Google Scholar 

  14. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003; 170: 1259–63

    Article  PubMed  CAS  Google Scholar 

  15. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187(1): 40–8

    Article  PubMed  CAS  Google Scholar 

  16. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine vs placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004; 111: 249–57

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Older pharmacological therapies for stress urinary incontinence are often unreliable, but duloxetine is a promising new option. Drugs Ther. Perspect 21, 12–15 (2005). https://doi.org/10.2165/00042310-200521060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521060-00004

Search

Navigation